Publications 2024

Machak GN, Bruland ØS, Romanova TN, Kovalev AV (2024)
Denosumab induction and Zoledronic acid maintenance therapy for recurrent unresectable giant cell tumour of the distal tibia: A case report with sustained tumour control after drug withdrawal
J Bone Oncol, 45, 100596
DOI 10.1016/j.jbo.2024.100596, PubMed 38545297

Publications 2023

Bruland ØS, Larsen RH, Baum RP, Juzeniene A (2023)
Editorial: Targeted alpha particle therapy in oncology
Front Med (Lausanne), 10, 1165747
DOI 10.3389/fmed.2023.1165747, PubMed 36960341

Fauske L, Jebsen NL, Bondevik H, Bruland ØS (2023)
Exploring the Patient Perspective of Bone Sarcoma Survivors Who Have Undergone Particle Radiotherapy Abroad
Anticancer Res, 43 (5), 2031-2039
DOI 10.21873/anticanres.16364, PubMed 37097689

Grønningsæter SR, Blakkisrud J, Selboe S, Revheim ME, Bruland ØS, Bønsdorff TB, Larsen SG, Stokke C (2023)
Radiation safety considerations for the use of radium-224-calciumcarbonate-microparticles in patients with peritoneal metastasis
Front Med (Lausanne), 10, 1058914
DOI 10.3389/fmed.2023.1058914, PubMed 36844217

Juzeniene A, Stenberg VY, Bruland ØS, Revheim ME, Larsen RH (2023)
Dual targeting with ²²⁴Ra/²¹²Pb-conjugates for targeted alpha therapy of disseminated cancers: A conceptual approach
Front Med (Lausanne), 9, 1051825
DOI 10.3389/fmed.2022.1051825, PubMed 36733936

Larsen SG, Graf W, Mariathasan AB, Sørensen O, Spasojevic M, Goscinski MA, Selboe S, Lundstrøm N, Holtermann A, Revheim ME, Bruland ØS (2023)
First experience with ²²⁴Radium-labeled microparticles (Radspherin®) after CRS-HIPEC for peritoneal metastasis in colorectal cancer (a phase 1 study)
Front Med (Lausanne), 10, 1070362
DOI 10.3389/fmed.2023.1070362, PubMed 36936230

Mensali N, Köksal H, Joaquina S, Wernhoff P, Casey NP, Romecin P, Panisello C, Rodriguez R, Vimeux L, Juzeniene A, Myhre MR, Fåne A, Ramírez CC, Maggadottir SM, Duru AD, Georgoudaki AM, Grad I, Maturana AD, Gaudernack G, Kvalheim G, Carcaboso AM, de Alava E, Donnadieu E, Bruland ØS, Menendez P et al. (2023)
ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma
Nat Commun, 14 (1), 3375
DOI 10.1038/s41467-023-39097-x, PubMed 37291203

Palmerini E, Reichardt P, Hall KS, Bertulli R, Bielack SS, Comandone A, Egerer G, Hansmeier A, Kevric M, Carretta E, Hansson L, Jebsen N, Eriksson M, Bruland ØS, Donati DM, Ibrahim T, Smeland S, Ferrari S (2023)
Outcome of rare primary malignant bone sarcoma treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma Study (EURO-B.O.S.S.)
Cancer, 129 (22), 3564-3573
DOI 10.1002/cncr.34964, PubMed 37530385

Thorgersen EB, Asvall J, Schjalm C, McAdam KE, Bruland ØS, Larsen SG, Mollnes TE (2023)
Effect of Intraperitoneal ²²⁴Radium-Labelled Microparticles on Compartmentalized Inflammation After Cytoreductive Surgery and Hypertherm Intraperitoneal Chemotherapy
Technol Cancer Res Treat, 22, 15330338231192902
DOI 10.1177/15330338231192902, PubMed 37574949

van de Wal D, Fauske L, Bruland ØS, Jones RL, Kasper B, Wilson R, van der Graaf WTA, Husson O (2023)
Psychological and social challenges of patients with locally advanced and metastatic gastrointestinal stromal tumours (GIST) on long-term treatment with tyrosine kinase inhibitors: a qualitative study with patients and medical oncologists
Support Care Cancer, 31 (6), 352
DOI 10.1007/s00520-023-07810-7, PubMed 37233829

Publications 2022

Barnes DJ, Dutton P, Bruland Ø, Gelderblom H, Faleti A, Bühnemann C, van Maldegem A, Johnson H, Poulton L, Love S, Tiemeier G, van Beelen E, Herbschleb K, Haddon C, Billingham L, Bradley K, Ferrari S, Palmerini E, Picci P, Dirksen U, Strauss SJ, Hogendoorn PCW, Buddingh E, Blay JY, Cleton-Jansen AM et al. (2022)
Outcomes from a mechanistic biomarker multi-arm and randomised study of liposomal MTP-PE (Mifamurtide) in metastatic and/or recurrent osteosarcoma (EuroSarc-Memos trial)
BMC Cancer, 22 (1), 629
DOI 10.1186/s12885-022-09697-9, PubMed 35672690

Boye K, Lobmaier I, Kobbeltvedt MR, Thorkildsen J, Taksdal I, Bjerkehagen B, Bruland ØS, Zaikova O, Sundby Hall K, Hompland I (2022)
Real-world evidence on perioperative chemotherapy in localized soft tissue sarcoma of the extremities and trunk wall; a population-based study
Acta Oncol, 61 (7), 793-800
DOI 10.1080/0284186X.2022.2082259, PubMed 35698755

Fauske L, Wærstad PH, Hompland I, Bruland ØS (2022)
Hope as a Lifeline: Imatinib Discontinuation in Patients With Oligometastatic Gastrointestinal Stromal Tumours
Anticancer Res, 42 (2), 955-963
DOI 10.21873/anticanres.15555, PubMed 35093895

Schmid MP, Harrabi S, Herfarth K, Bruland ØS, Welzel T, Haberer T, Ellerbrock M, Debus J, Uhl M, Seidensaal K (2022)
Particle Therapy in Adult Patients with Pelvic Ewing Sarcoma-Tumor and Treatment Characteristics and Early Clinical Outcomes
Cancers (Basel), 14 (24)
DOI 10.3390/cancers14246045, PubMed 36551530

Stenberg VY, Tornes AJK, Nilsen HR, Revheim ME, Bruland ØS, Larsen RH, Juzeniene A (2022)
Factors Influencing the Therapeutic Efficacy of the PSMA Targeting Radioligand ²¹²Pb-NG001
Cancers (Basel), 14 (11)
DOI 10.3390/cancers14112784, PubMed 35681766

Tornes AJK, Stenberg VY, Larsen RH, Bruland ØS, Revheim ME, Juzeniene A (2022)
Targeted alpha therapy with the ²²⁴Ra/²¹²Pb-TCMC-TP-3 dual alpha solution in a multicellular tumor spheroid model of osteosarcoma
Front Med (Lausanne), 9, 1058863
DOI 10.3389/fmed.2022.1058863, PubMed 36507500

Publications 2021

Fauske L, Bruland ØS, Dahl AA, Myklebostad A, Reme SE (2021)
Does the Lightning Process Training Programme Reduce Chronic Fatigue in Adolescent and Young Adult Cancer Survivors? A Mixed-Methods Pilot Study
Cancers (Basel), 13 (16)
DOI 10.3390/cancers13164076, PubMed 34439229

Juzeniene A, Stenberg VY, Bruland ØS, Larsen RH (2021)
Preclinical and Clinical Status of PSMA-Targeted Alpha Therapy for Metastatic Castration-Resistant Prostate Cancer
Cancers (Basel), 13 (4)
DOI 10.3390/cancers13040779, PubMed 33668474

Kerboeuf M, Koppang EO, Haaland AH, Lingaas F, Bruland ØS, Teige J, Moe L (2021)
Early immunohistochemical detection of pulmonary micrometastases in dogs with osteosarcoma
Acta Vet Scand, 63 (1), 41
DOI 10.1186/s13028-021-00608-9, PubMed 34732227

Lansu J, Bovée JVMG, Braam P, van Boven H, Flucke U, Bonenkamp JJ, Miah AB, Zaidi SH, Thway K, Bruland ØS, Baldini EH, Jebsen NL, Scholten AN, van den Ende PLA, Krol ADG, Ubbels JF, van der Hage JA, van Werkhoven E, Klomp HM, van der Graaf WTA, van Coevorden F, Schrage Y, van Houdt WJ, Haas RL (2021)
Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma: A Nonrandomized Controlled Trial
JAMA Oncol, 7 (1), e205865
DOI 10.1001/jamaoncol.2020.5865, PubMed 33180100

Li RG, Napoli E, Jorstad IS, Bønsdorff TB, Juzeniene A, Bruland ØS, Larsen RH, Westrøm S (2021)
Calcium Carbonate Microparticles as Carriers of ²²⁴Ra: Impact of Specific Activity in Mice with Intraperitoneal Ovarian Cancer
Curr Radiopharm, 14 (2), 145-153
DOI 10.2174/1874471013666201201102056, PubMed 33261548

Napoli E, Bønsdorff TB, Jorstad IS, Bruland ØS, Larsen RH, Westrøm S (2021)
Radon-220 diffusion from 224Ra-labeled calcium carbonate microparticles: Some implications for radiotherapeutic use
PLoS One, 16 (3), e0248133
DOI 10.1371/journal.pone.0248133, PubMed 33662039

Revheim ME, Hole KH, Mo T, Bruland ØS, Reitan E, Julsrud L, Seierstad T (2021)
Multimodal functional imaging for early response assessment in patients with gastrointestinal stromal tumor treated with tyrosine kinase inhibitors
Acta Radiol, 63 (8), 995-1004
DOI 10.1177/02841851211027389, PubMed 34171968

Spasojevic M, Mariathasan AB, Frich L, Bruland ØS, Larsen SG, Stoldt S (2021)
[Cancer therapy with isolated limb perfusion]
Tidsskr Nor Laegeforen, 141 (2021-12)
DOI 10.4045/tidsskr.21.0194, PubMed 34505491

Stenberg VY, Larsen RH, Ma LW, Peng Q, Juzenas P, Bruland ØS, Juzeniene A (2021)
Evaluation of the PSMA-Binding Ligand ²¹²Pb-NG001 in Multicellular Tumour Spheroid and Mouse Models of Prostate Cancer
Int J Mol Sci, 22 (9)
DOI 10.3390/ijms22094815, PubMed 34062920

van Eck I, den Hollander D, Lidington E, Hentschel L, Eichler M, Salah S, Singer S, Pinto M, Fauske L, Fiore M, Nixon I, Constantinidou A, Desar IME, Bonenkamp JJ, van Houdt WJ, Reuvers MJP, Haas RLM, Bruland ØS, Kasper B, van der Graaf WTA, Husson O (2021)
Health-Related Quality of Life Issues Experienced by Thoracic and Breast Sarcoma Patients: A Rare and Understudied Group
J Clin Med, 10 (22)
DOI 10.3390/jcm10225334, PubMed 34830615

Publications 2020

Hall KS, Bruland ØS, Bjerkehagen B, Lidbrink E, Jebsen N, Hagberg H, Papworth K, Hagberg O, Trovik C, Bauer H, Eriksson M (2020)
Preoperative accelerated radiotherapy combined with chemotherapy in a defined cohort of patients with high risk soft tissue sarcoma: a Scandinavian Sarcoma Group study
Clin Sarcoma Res, 10 (1), 22
DOI 10.1186/s13569-020-00145-5, PubMed 33292545

Hompland I, Fauske L, Lorem GF, Bruland ØS (2020)
Use of a simple form to facilitate communication on long-term consequences of treatment in sarcoma survivors
Clin Sarcoma Res, 10, 2
DOI 10.1186/s13569-019-0124-3, PubMed 31969978

König M, Osnes T, Bruland Ø, Sundby Hall K, Bratland Å, Meling TR (2020)
The Role of Adjuvant Treatment in Craniofacial Malignancy: A Critical Review
Front Oncol, 10, 1402
DOI 10.3389/fonc.2020.01402, PubMed 32850452

Napoli E, Stenberg VY, Juzeniene A, Hjellum GE, Bruland ØS, Larsen RH (2020)
Calibration of sodium iodide detectors and reentrant ionization chambers for ²¹²Pb activity in different geometries by HPGe activity determined samples
Appl Radiat Isot, 166, 109362
DOI 10.1016/j.apradiso.2020.109362, PubMed 32979756

Stenberg VY, Juzeniene A, Bruland ØS, Larsen RH (2020)
In situ Generated ²¹²Pb-PSMA Ligand in a ²²⁴Ra-Solution for Dual Targeting of Prostate Cancer Sclerotic Stroma and PSMA-positive Cells
Curr Radiopharm, 13 (2), 130-141
DOI 10.2174/1874471013666200511000532, PubMed 32389119

Stenberg VY, Juzeniene A, Chen Q, Yang X, Bruland ØS, Larsen RH (2020)
Preparation of the alpha-emitting prostate-specific membrane antigen targeted radioligand [²¹² Pb]Pb-NG001 for prostate cancer
J Labelled Comp Radiopharm, 63 (3), 129-143
DOI 10.1002/jlcr.3825, PubMed 31919866

Publications 2019

Berner K, Bruland ØS (2019)
Prognostic Impact of Proximal Versus Distal Localization in Extremity Long Bone Osteosarcomas
Anticancer Res, 39 (5), 2459-2466
DOI 10.21873/anticanres.13365, PubMed 31092440

Fauske L, Hompland I, Lorem G, Bondevik H, Bruland ØS (2019)
Perspectives on treatment side effects in patients with metastatic gastrointestinal stromal tumour: a qualitative study
Clin Sarcoma Res, 9, 6
DOI 10.1186/s13569-019-0116-3, PubMed 31061697

Jha AK, Neupane P, Pradhan M, Sharma KS, Shrestha S, Sigdel PR, Smeland S, Bruland ØS (2019)
Ewing Sarcoma in Nepal Treated With Combined Chemotherapy and Definitive Radiotherapy
J Glob Oncol, 5, 1-10
DOI 10.1200/JGO.19.00015, PubMed 30917070

Köksal H, Müller E, Inderberg EM, Bruland Ø, Wälchli S (2019)
Treating osteosarcoma with CAR T cells
Scand J Immunol, 89 (3), e12741
DOI 10.1111/sji.12741, PubMed 30549299

Thorkildsen J, Taksdal I, Bjerkehagen B, Haugland HK, Børge Johannesen T, Viset T, Norum OJ, Bruland Ø, Zaikova O (2019)
Chondrosarcoma in Norway 1990-2013; an epidemiological and prognostic observational study of a complete national cohort
Acta Oncol, 58 (3), 273-282
DOI 10.1080/0284186X.2018.1554260, PubMed 30632866

Publications 2018

Berner K, Johannesen TB, Hall KS, Bruland ØS (2018)
Clinical epidemiology and treatment outcomes of spindle cell non-osteogenic bone sarcomas - A nationwide population-based study
J Bone Oncol, 14, 002-2
DOI 10.1016/j.jbo.2018.11.002, PubMed 30568874

Berner K, Zaikova O, Johannesen TB, Hall KS, Bruland ØS (2018)
Validity and completeness of the Scandinavian Sarcoma Group Central Register by comparison with a nationwide cohort of patients with osteosarcoma in Norway
J Surg Oncol, 118 (1), 246-247
DOI 10.1002/jso.25137, PubMed 30208205

Boye K, Berner JM, Hompland I, Bruland ØS, Stoldt S, Sundby Hall K, Bjerkehagen B, Hølmebakk T (2018)
Genotype and risk of tumour rupture in gastrointestinal stromal tumour
Br J Surg, 105 (2), e169-e175
DOI 10.1002/bjs.10743, PubMed 29341147

Heinrich D, Bruland Ø, Guise TA, Suzuki H, Sartor O (2018)
Alkaline phosphatase in metastatic castration-resistant prostate cancer: reassessment of an older biomarker
Future Oncol, 14 (24), 2543-2556
DOI 10.2217/fon-2018-0087, PubMed 29925281

Herlofson BB, Kjølle GK, Westgaard KL, Løndalen AM, Bruland ØS (2018)
Osteonecrosis of the Jaw in a Patient With Bone Metastatic Prostate Cancer After Long-term Bisphosphonate Treatment With Severe Deterioration Following Radium-223
Clin Genitourin Cancer, 16 (5), 328-331
DOI 10.1016/j.clgc.2018.05.003, PubMed 29861164

Hesla AC, Bruland ØS, Jebsen N, Styring E, Eriksson S, Tsagozis P (2018)
Ewing sarcoma of the mobile spine; predictive factors for survival, neurological function and local control. A Scandinavian sarcoma group study with a mean follow-up of 12 years
J Bone Oncol, 14, 100216
DOI 10.1016/j.jbo.2018.100216, PubMed 30666289

Hompland I, Hølmebakk T, Boye K, Stoldt S, Bjerkehagen B, Berner JM, Wiedswang AM, Revheim ME, Poulsen JP, Hall KS, Bruland ØS (2018)
[Not Available]
Tidsskr Nor Laegeforen, 138 (15)
DOI 10.4045/tidsskr.18.0200, PubMed 30277049

Hølmebakk T, Hompland I, Bjerkehagen B, Stoldt S, Bruland ØS, Hall KS, Boye K (2018)
Recurrence-Free Survival After Resection of Gastric Gastrointestinal Stromal Tumors Classified According to a Strict Definition of Tumor Rupture: A Population-Based Study
Ann Surg Oncol, 25 (5), 1133-1139
DOI 10.1245/s10434-018-6353-5, PubMed 29435684

Sundby Hall K, Bruland ØS, Bjerkehagen B, Zaikova O, Engellau J, Hagberg O, Hansson L, Hagberg H, Ahlström M, Knobel H, Papworth K, Zemmler M, Goplen D, Bauer HCF, Eriksson M (2018)
Adjuvant chemotherapy and postoperative radiotherapy in high-risk soft tissue sarcoma patients defined by biological risk factors-A Scandinavian Sarcoma Group study (SSG XX)
Eur J Cancer, 99, 78-85
DOI 10.1016/j.ejca.2018.05.011, PubMed 29929092

Westrøm S, Bønsdorff TB, Bruland ØS, Larsen RH (2018)
Therapeutic Effect of α-Emitting ²²⁴Ra-Labeled Calcium Carbonate Microparticles in Mice with Intraperitoneal Ovarian Cancer
Transl Oncol, 11 (2), 259-267
DOI 10.1016/j.tranon.2017.12.011, PubMed 29413758

Westrøm S, Malenge M, Jorstad IS, Napoli E, Bruland ØS, Bønsdorff TB, Larsen RH (2018)
Ra-224 labeling of calcium carbonate microparticles for internal α-therapy: Preparation, stability, and biodistribution in mice
J Labelled Comp Radiopharm, 61 (6), 472-486
DOI 10.1002/jlcr.3610, PubMed 29380410

Publications 2017

Hompland I, Bruland ØS, Hølmebakk T, Poulsen JP, Stoldt S, Hall KS, Boye K (2017)
Prediction of long-term survival in patients with metastatic gastrointestinal stromal tumor: analysis of a large, single-institution cohort
Acta Oncol, 56 (10), 1317-1323
DOI 10.1080/0284186X.2017.1330555, PubMed 28557540

Parker CC, Coleman RE, Sartor O, Vogelzang NJ, Bottomley D, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzén L, Bruland ØS et al. (2017)
Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial
Eur Urol, 73 (3), 427-435
DOI 10.1016/j.eururo.2017.06.021, PubMed 28705540

Sartor O, Coleman RE, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Vogelzang NJ, Bruland Ø, Kobina S, Wilhelm S, Xu L, Shan M, Kattan MW, Parker C (2017)
An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223
Ann Oncol, 28 (5), 1090-1097
DOI 10.1093/annonc/mdx044, PubMed 28453701

Publications 2016

Barøy T, Chilamakuri CS, Lorenz S, Sun J, Bruland ØS, Myklebost O, Meza-Zepeda LA (2016)
Genome Analysis of Osteosarcoma Progression Samples Identifies FGFR1 Overexpression as a Potential Treatment Target and CHM as a Candidate Tumor Suppressor Gene
PLoS One, 11 (9), e0163859
DOI 10.1371/journal.pone.0163859, PubMed 27685995

Hompland I, Bruland ØS, Ubhayasekhera K, Bergquist J, Boye K (2016)
Clinical implications of repeated drug monitoring of imatinib in patients with metastatic gastrointestinal stromal tumour
Clin Sarcoma Res, 6, 21
DOI 10.1186/s13569-016-0062-2, PubMed 27999655

Hølmebakk T, Bjerkehagen B, Boye K, Bruland Ø, Stoldt S, Sundby Hall K (2016)
Definition and clinical significance of tumour rupture in gastrointestinal stromal tumours of the small intestine
Br J Surg, 103 (6), 684-691
DOI 10.1002/bjs.10104, PubMed 26988241

König M, Osnes TA, Lobmaier I, Bjerkehagen B, Bruland ØS, Sundby Hall K, Meling TR (2016)
Multimodal treatment of craniofacial osteosarcoma with high-grade histology. A single-center experience over 35 years
Neurosurg Rev, 40 (3), 449-460
DOI 10.1007/s10143-016-0802-z, PubMed 27858303

Parker C, Finkelstein SE, Michalski JM, O'Sullivan JM, Bruland Ø, Vogelzang NJ, Coleman RE, Nilsson S, Sartor O, Li R, Seger MA, Bottomley D (2016)
Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial
Eur Urol, 70 (5), 875-883
DOI 10.1016/j.eururo.2016.06.002, PubMed 27344296

Varghese M, Bruland O, Wiedswang AM, Lobmaier I, Røsok B, Benjamin RS, Hall KS (2016)
Metastatic mesenteric dedifferentiated leiomyosarcoma: a case report and a review of literature
Clin Sarcoma Res, 6, 2
DOI 10.1186/s13569-016-0042-6, PubMed 26913180

Westrøm S, Bønsdorff TB, Abbas N, Bruland ØS, Jonasdottir TJ, Mælandsmo GM, Larsen RH (2016)
Evaluation of CD146 as Target for Radioimmunotherapy against Osteosarcoma
PLoS One, 11 (10), e0165382
DOI 10.1371/journal.pone.0165382, PubMed 27776176

Publications 2015

Anfinsen KP, Grotmol T, Bruland OS, Cathrine T, Jonasdottir TJ (2015)
Corrigendum to "Primary bone cancer in Leonbergers may be associated with a higher bodyweight during adolescence" [Prev. Vet. Med. 119 (2015) 48-53]
Prev Vet Med, 120 (2), 252
DOI 10.1016/j.prevetmed.2015.03.015, PubMed 31159133

Anfinsen KP, Grotmol T, Bruland OS, Trangerud C, Jonasdottir TJ (2015)
Primary bone cancer in Leonbergers may be associated with a higher bodyweight during adolescence
Prev Vet Med, 119 (1-2), 48-53
DOI 10.1016/j.prevetmed.2015.02.003, PubMed 25732913

Berner K, Bjerkehagen B, Bruland ØS, Berner A (2015)
Extraskeletal osteosarcoma in Norway, between 1975 and 2009, and a brief review of the literature
Anticancer Res, 35 (4), 2129-40
PubMed 25862869

Berner K, Hall KS, Monge OR, Weedon-Fekjær H, Zaikova O, Bruland ØS (2015)
Prognostic factors and treatment results of high-grade osteosarcoma in norway: a scope beyond the "classical" patient
Sarcoma, 2015, 516843
DOI 10.1155/2015/516843, PubMed 25784831

Berner K, Johannesen TB, Bruland ØS (2015)
Clinical Epidemiology of Low-Grade and Dedifferentiated Osteosarcoma in Norway during 1975 and 2009
Sarcoma, 2015, 917679
DOI 10.1155/2015/917679, PubMed 26412976

Fauske L, Bondevik H, Bruland ØS, Ozakinci G (2015)
Negative and Positive Consequences of Cancer Treatment Experienced by Long-term Osteosarcoma Survivors: A Qualitative Study
Anticancer Res, 35 (11), 6081-90
PubMed 26504033

Fauske L, Bruland OS, Grov EK, Bondevik H (2015)
Cured of primary bone cancer, but at what cost: a qualitative study of functional impairment and lost opportunities
Sarcoma, 2015, 484196
DOI 10.1155/2015/484196, PubMed 25949211

Hompland I, Bruland ØS (2015)
Can Imatinib Be Safely Withdrawn in Patients with Surgically Resected Metastatic GIST?
Anticancer Res, 35 (11), 5759-65
PubMed 26503996

Humm JL, Sartor O, Parker C, Bruland OS, Macklis R (2015)
Radium-223 in the treatment of osteoblastic metastases: a critical clinical review
Int J Radiat Oncol Biol Phys, 91 (5), 898-906
DOI 10.1016/j.ijrobp.2014.12.061, PubMed 25832684

Juzeniene A, Baturaite Z, Lagunova Z, Grigalavicius M, Porojnicu AC, Bruland ØS, Moan J (2015)
Influence of multiple UV exposures on serum cobalamin and vitamin D levels in healthy females
Scand J Public Health, 43 (3), 324-30
DOI 10.1177/1403494815572206, PubMed 25740614

Juzeniene A, Porojnicu AC, Baturaite Z, Lagunova Z, Aksnes L, Bruland ØS, Moan J (2015)
Vitamin D levels and dietary intake among patients with benign soft tissue tumors and sarcomas
Anticancer Res, 35 (2), 1171-80
PubMed 25667508

Publications 2014

Berner K, Johannesen TB, Berner A, Haugland HK, Bjerkehagen B, Bøhler PJ, Bruland ØS (2014)
Time-trends on incidence and survival in a nationwide and unselected cohort of patients with skeletal osteosarcoma
Acta Oncol, 54 (1), 25-33
DOI 10.3109/0284186X.2014.923934, PubMed 24957555

Ohnstad HO, Bruland OS, Taksdal I, Bjerkehagen B, Nenadovic M, Sæter G, Jørgensen LH, Hall KS (2014)
Response to preoperative chemotherapy in patients undergoing resection of pulmonary metastasis from soft tissue sarcoma - a predictor of outcome?
Acta Oncol, 53 (9), 1180-7
DOI 10.3109/0284186X.2014.899433, PubMed 24697744

Repetto-Llamazares A, Abbas N, Bruland ØS, Dahle J, Larsen RH (2014)
Advantage of lutetium-177 versus radioiodine immunoconjugate in targeted radionuclide therapy of b-cell tumors
Anticancer Res, 34 (7), 3263-9
PubMed 24982330

Repetto-Llamazares AH, Larsen RH, Giusti AM, Riccardi E, Bruland ØS, Selbo PK, Dahle J (2014)
177Lu-DOTA-HH1, a novel anti-CD37 radio-immunoconjugate: a study of toxicity in nude mice
PLoS One, 9 (7), e103070
DOI 10.1371/journal.pone.0103070, PubMed 25068508

Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Widmark A, Johannessen DC, Hoskin P, James ND, Solberg A, Syndikus I, Vogelzang NJ, O'Bryan-Tear CG, Shan M, Bruland ØS, Parker C (2014)
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial
Lancet Oncol, 15 (7), 738-46
DOI 10.1016/S1470-2045(14)70183-4, PubMed 24836273

Switlyk MD, Bruland ØS, Skjeldal S, Hald JK, Seierstad T, Zaikova O (2014)
Radiotherapy for spinal metastases from breast cancer with emphasis on local disease control and pain response using repeated MRI
J Bone Oncol, 3 (1), 5-9
DOI 10.1016/j.jbo.2014.02.003, PubMed 26909292

Publications 2013

Abbas N, Heyerdahl H, Bruland ØS, Brevik EM, Dahle J (2013)
Comparing high LET 227Th- and low LET 177Lu-trastuzumab in mice with HER-2 positive SKBR-3 xenografts
Curr Radiopharm, 6 (2), 78-86
DOI 10.2174/18744710113069990017, PubMed 23551110

Bjerkehagen B, Småstuen MC, Hall KS, Skjeldal S, Bruland ØS, Smeland S, Johannesen TB, Fosså SD (2013)
Incidence and mortality of second sarcomas - a population-based study
Eur J Cancer, 49 (15), 3292-302
DOI 10.1016/j.ejca.2013.05.017, PubMed 23787025

Dahle J, Repetto-Llamazares AH, Mollatt CS, Melhus KB, Bruland OS, Kolstad A, Larsen RH (2013)
Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma
Anticancer Res, 33 (1), 85-95
PubMed 23267131

Fløisand Y, Beiske K, Tjønnfjord GE, Heldal D, Bjerkehagen B, Revheim ME, Heim S, Bruland OS, Hall KS, Tierens A, Delabie J (2013)
Malignant phyllodes tumor and acute megakaryoblastic leukemia sharing a common clonal origin
Case Rep Hematol, 2013, 934781
DOI 10.1155/2013/934781, PubMed 24455338

Heyerdahl H, Abbas N, Sponheim K, Mollatt C, Bruland Ø, Dahle J (2013)
Targeted alpha therapy with 227Th-trastuzumab of intraperitoneal ovarian cancer in nude mice
Curr Radiopharm, 6 (2), 106-16
DOI 10.2174/18744710113069990018, PubMed 23551111

Jebsen NL, Engellau J, Engström K, Bauer HC, Monge OR, Muren LP, Eide GE, Trovik CS, Bruland OS (2013)
Patterns of local recurrence and dose fractionation of adjuvant radiation therapy in 462 patients with soft tissue sarcoma of extremity and trunk wall
Int J Radiat Oncol Biol Phys, 86 (5), 949-55
DOI 10.1016/j.ijrobp.2013.04.015, PubMed 23725998

Lagunova Z, Porojnicu AC, Aksnes L, Holick MF, Iani V, Bruland OS, Moan J (2013)
Effect of vitamin D supplementation and ultraviolet B exposure on serum 25-hydroxyvitamin D concentrations in healthy volunteers: a randomized, crossover clinical trial
Br J Dermatol, 169 (2), 434-40
DOI 10.1111/bjd.12349, PubMed 23551243

Lia K, Bruland ØS, Randem HL, Aksnes LH, Poulsen JP, Taksdal I, Sundby Hall K (2013)
Two cases with fatal outcome following total lung irradiation for metastatic bone sarcoma
J Bone Oncol, 2 (4), 174-9
DOI 10.1016/j.jbo.2013.09.002, PubMed 26909289

Mikalsen LT, Dhakal HP, Bruland ØS, Naume B, Borgen E, Nesland JM, Olsen DR (2013)
The clinical impact of mean vessel size and solidity in breast carcinoma patients
PLoS One, 8 (10), e75954
DOI 10.1371/journal.pone.0075954, PubMed 24146798

Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzén L, Coleman R, Vogelzang NJ, O'Bryan-Tear CG et al. (2013)
Alpha emitter radium-223 and survival in metastatic prostate cancer
N Engl J Med, 369 (3), 213-23
DOI 10.1056/NEJMoa1213755, PubMed 23863050

Revheim ME, Hole KH, Bruland OS, Reitan E, Bjerkehagen B, Julsrud L, Seierstad T (2013)
Multimodal functional imaging for early response assessment in GIST patients treated with imatinib
Acta Oncol, 53 (1), 143-8
DOI 10.3109/0284186X.2013.798428, PubMed 23710697

Revheim ME, Kristian A, Malinen E, Bruland ØS, Berner JM, Holm R, Joensuu H, Seierstad T (2013)
Intermittent and continuous imatinib in a human GIST xenograft model carrying KIT exon 17 resistance mutation D816H
Acta Oncol, 52 (4), 776-82
DOI 10.3109/0284186X.2013.770920, PubMed 23480638

Rusten E, Rødal J, Bruland Ø, Malinen E (2013)
Biologic targets identified from dynamic 18FDG-PET and implications for image-guided therapy
Acta Oncol, 52 (7), 1378-83
DOI 10.3109/0284186X.2013.813071, PubMed 23981046

Publications 2012

Abbas N, Bruland ØS, Brevik EM, Dahle J (2012)
Preclinical evaluation of 227Th-labeled and 177Lu-labeled trastuzumab in mice with HER-2-positive ovarian cancer xenografts
Nucl Med Commun, 33 (8), 838-47
DOI 10.1097/MNM.0b013e328354df7c, PubMed 22643311

Micu E, Baturaite Z, Juzeniene A, Bruland ØS, Moan JE (2012)
Superficial-spreading and nodular melanomas in Norway: a comparison by body site distribution and latitude gradients
Melanoma Res, 22 (6), 460-5
DOI 10.1097/CMR.0b013e3283599cc3, PubMed 23010822

Namløs HM, Kresse SH, Müller CR, Henriksen J, Holdhus R, Sæter G, Bruland OS, Bjerkehagen B, Steen VM, Myklebost O (2012)
Global gene expression profiling of human osteosarcomas reveals metastasis-associated chemokine pattern
Sarcoma, 2012, 639038
DOI 10.1155/2012/639038, PubMed 22518090

Nilsson S, Franzén L, Parker C, Tyrrell C, Blom R, Tennvall J, Lennernäs B, Petersson U, Johannessen DC, Sokal M, Pigott K, O'Bryan-Tear CG, Thuresson M, Bolstad B, Bruland ØS (2012)
Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases
Clin Genitourin Cancer, 11 (1), 20-6
DOI 10.1016/j.clgc.2012.07.002, PubMed 23021204

Nilsson S, Strang P, Aksnes AK, Franzèn L, Olivier P, Pecking A, Staffurth J, Vasanthan S, Andersson C, Bruland ØS (2012)
A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer
Eur J Cancer, 48 (5), 678-86
DOI 10.1016/j.ejca.2011.12.023, PubMed 22341993

Rusten E, Rødal J, Revheim ME, Skretting A, Bruland OS, Malinen E (2012)
Quantitative dynamic ¹⁸FDG-PET and tracer kinetic analysis of soft tissue sarcomas
Acta Oncol, 52 (6), 1160-7
DOI 10.3109/0284186X.2012.728713, PubMed 23198721

Sartor O, Hoskin P, Bruland OS (2012)
Targeted radio-nuclide therapy of skeletal metastases
Cancer Treat Rev, 39 (1), 18-26
DOI 10.1016/j.ctrv.2012.03.006, PubMed 22534284

Publications 2011

Abbas N, Heyerdahl H, Bruland OS, Borrebæk J, Nesland J, Dahle J (2011)
Experimental α-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTA-trastuzumab
EJNMMI Res, 1 (1), 18
DOI 10.1186/2191-219X-1-18, PubMed 22214432

Anfinsen KP, Devesa SS, Bray F, Troisi R, Jonasdottir TJ, Bruland OS, Grotmol T (2011)
Age-period-cohort analysis of primary bone cancer incidence rates in the United States (1976-2005)
Cancer Epidemiol Biomarkers Prev, 20 (8), 1770-7
DOI 10.1158/1055-9965.EPI-11-0136, PubMed 21724855

Anfinsen KP, Grotmol T, Bruland OS, Jonasdottir TJ (2011)
Breed-specific incidence rates of canine primary bone tumors--a population based survey of dogs in Norway
Can J Vet Res, 75 (3), 209-15
PubMed 22210997

Dahle J, Abbas N, Bruland ØS, Larsen RH (2011)
Toxicity and relative biological effectiveness of alpha emitting radioimmunoconjugates
Curr Radiopharm, 4 (4), 321-8
DOI 10.2174/1874471011104040321, PubMed 22202154

Mikalsen LT, Dhakal HP, Bruland OS, Nesland JM, Olsen DR (2011)
Quantification of angiogenesis in breast cancer by automated vessel identification in CD34 immunohistochemical sections
Anticancer Res, 31 (12), 4053-60
PubMed 22199261

Revheim ME, Røe K, Bruland ØS, Bach-Gansmo T, Skretting A, Seierstad T (2011)
Monitoring the effect of targeted therapies in a gastrointestinal stromal tumor xenograft using a clinical PET/CT
Mol Imaging Biol, 13 (6), 1234-40
DOI 10.1007/s11307-010-0464-0, PubMed 21161686

Sartor O, Bruland O (2011)
Stromal targeted therapies in prostate and renal cancer: new concepts and knowledge
Clin Genitourin Cancer, 9 (1), 1-2
DOI 10.1016/j.clgc.2011.08.001, PubMed 21925102

Sartor O, Goeckeler W, Bruland O (2011)
Stromal targeted therapy in bone metastatic prostate cancer: promise delivered
Asian J Androl, 13 (6), 783-4
DOI 10.1038/aja.2011.120, PubMed 21857688

Smeland S, Bruland OS, Hjorth L, Brosjö O, Bjerkehagen B, Osterlundh G, Jakobson A, Hall KS, Monge OR, Björk O, Alvegaard TA (2011)
Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma: 63 patients with a minimum follow-up of 4 years
Acta Orthop, 82 (2), 211-6
DOI 10.3109/17453674.2011.566141, PubMed 21434784

Zaikova O, Fosså SD, Bruland OS, Giercksky KE, Sandstad B, Skjeldal S (2011)
Radiotherapy or surgery for spine metastases?
Acta Orthop, 82 (3), 365-71
DOI 10.3109/17453674.2011.566142, PubMed 21434789

Publications 2010

Cicarma E, Juzeniene A, Porojnicu AC, Bruland ØS, Moan J (2010)
Latitude gradient for melanoma incidence by anatomic site and gender in Norway 1966-2007
J Photochem Photobiol B, 101 (2), 174-8
DOI 10.1016/j.jphotobiol.2010.04.002, PubMed 20430639

Dale E, Hårsaker V, Kristoffersen DT, Bruland O, Olsen DR (2010)
CT density in lung cancer patients after radiotherapy sensitized by metoclopramide. A subgroup analysis of a randomized trial
Strahlenther Onkol, 186 (3), 163-8
DOI 10.1007/s00066-010-2040-6, PubMed 20165821

Jebsen NL, Bruland ØS, Eriksson M, Engellau J, Turesson I, Folin A, Trovik CS, Hall KS (2010)
Five-year results from a Scandinavian sarcoma group study (SSG XIII) of adjuvant chemotherapy combined with accelerated radiotherapy in high-risk soft tissue sarcoma of extremities and trunk wall
Int J Radiat Oncol Biol Phys, 81 (5), 1359-66
DOI 10.1016/j.ijrobp.2010.07.037, PubMed 20933339

Lagunova Z, Porojnicu AC, Grant WB, Bruland Ø, Moan JE (2010)
Obesity and increased risk of cancer: does decrease of serum 25-hydroxyvitamin D level with increasing body mass index explain some of the association?
Mol Nutr Food Res, 54 (8), 1127-33
DOI 10.1002/mnfr.200900512, PubMed 20512788

Moan J, Lagunova Z, Bruland O, Juzeniene A (2010)
Seasonal variations of cancer incidence and prognosis
Dermatoendocrinol, 2 (2), 55-7
DOI 10.4161/derm.2.2.12664, PubMed 21547098

Revheim ME, Hole KH, Bruland OS, Haugland HK, Hall KS, Seierstad T (2010)
DW MRI for evaluation of treatment response to imatinib in a rectal gastrointestinal stromal tumour
Acta Oncol, 50 (1), 148-50
DOI 10.3109/0284186X.2010.516273, PubMed 21110775

Publications 2009

Berg A, Dahl AA, Bruland ØS, Bjøro T, Aanensen MS, Fosså SD (2009)
Definitive radiotherapy with adjuvant long-term antiandrogen treatment for locally advanced prostate cancer: health-related quality of life and hormonal changes
Prostate Cancer Prostatic Dis, 12 (3), 269-76
DOI 10.1038/pcan.2009.8, PubMed 19290019

Brandal P, Bjerkehagen B, Bruland OS, Skjeldal S, Bogsrud TV, Hall KS (2009)
Synchronous and metachronous skeletal osteosarcomas: the Norwegian Radium Hospital experience
Acta Oncol, 48 (8), 1165-72
DOI 10.3109/02841860903032809, PubMed 19863225

Bruland ØS, Bauer H, Alvegaard T, Smeland S (2009)
Treatment of osteosarcoma. The Scandinavian Sarcoma Group experience
Cancer Treat Res, 152, 309-18
DOI 10.1007/978-1-4419-0284-9_16, PubMed 20213398

Bruland ØS, Høifødt H, Hall KS, Smeland S, Fodstad Ø (2009)
Bone marrow micrometastases studied by an immunomagnetic isolation procedure in extremity localized non-metastatic osteosarcoma patients
Cancer Treat Res, 152, 509-15
DOI 10.1007/978-1-4419-0284-9_30, PubMed 20213412

Hall KS, Eriksson M, Bruland OS, Engellau J, Trovik CS (2009)
Treatment of soft tissue sarcoma of the extremity and trunk wall The Scandinavian Sarcoma Group perspective
Acta Orthop., 80 334, 52-59

Norum OJ, Bruland ØS, Gorunova L, Berg K (2009)
Photochemical internalization of bleomycin before external-beam radiotherapy improves locoregional control in a human sarcoma model
Int J Radiat Oncol Biol Phys, 75 (3), 878-85
DOI 10.1016/j.ijrobp.2009.04.039, PubMed 19665318

Revheim ME, Seierstad T, Berner JM, Bruland OS, Røe K, Ohnstad HO, Bjerkehagen B, Bach-Gansmo T (2009)
Establishment and characterization of a human gastrointestinal stromal tumour (GIST) xenograft in athymic nude mice
Anticancer Res, 29 (11), 4331-6
PubMed 20032375

Sande TA, Ruenes R, Lund JA, Bruland OS, Hornslien K, Bremnes R, Kaasa S (2009)
Long-term follow-up of cancer patients receiving radiotherapy for bone metastases: results from a randomised multicentre trial
Radiother Oncol, 91 (2), 261-6
DOI 10.1016/j.radonc.2009.02.014, PubMed 19307034

Schwarz R, Bruland O, Cassoni A, Schomberg P, Bielack S (2009)
The role of radiotherapy in oseosarcoma
Cancer Treat Res, 152, 147-64
DOI 10.1007/978-1-4419-0284-9_7, PubMed 20213389

Smeland S, Bruland OS, Hjorth L, Brosjo O, Bjerkehagen B, Osterlundh G, Jakobson A, Hall KS, Monge OR, Bjork O, Alvegaard TA (2009)
Scandinavian experience in classical osteosarcoma Results of the SSG XIV protocol
Acta Orthop., 80 334, 60-66

Søvik S, Skogmo HK, Andersen EK, Bruland ØS, Olsen DR, Malinen E (2009)
DCEMRI of spontaneous canine tumors during fractionated radiotherapy: a pharmacokinetic analysis
Radiother Oncol, 93 (3), 618-24
DOI 10.1016/j.radonc.2009.08.012, PubMed 19747746

Publications 2008

Berg A, Bruland ØS, Fosså SD, Nesland JM, Berner A, Schirmer C, Lilleby W (2008)
Disseminated tumor cells in bone marrow following definitive radiotherapy for intermediate or high-risk prostate cancer
Prostate, 68 (15), 1607-14
DOI 10.1002/pros.20826, PubMed 18655095

Bruland OS, Jonasdottir TJ, Fisher DR, Larsen RH (2008)
Radium-223: From Radiochemical Development to Clinical Applications in Targeted Cancer Therapy
Curr. Radiopharm., 1 (3), 203-208
DOI 10.2174/1874471010801030203

Bruland S, Dahle J, Olsen DR, Larsen RH (2008)
Targeted high-LET therapy of bone metastases
In Targeted radionuclide tumor therapy. Biological aspects (Stigbrand T, Carlsson J, Adams GP, eds.), Springer Verlag
PublikaID 25, ISBN 978-1-4020-8695-3

Dahle J, Bruland OS, Larsen RH (2008)
Relative biologic effects of low-dose-rate alpha-emitting 227Th-rituximab and beta-emitting 90Y-tiuexetan-ibritumomab versus external beam X-radiation
Int J Radiat Oncol Biol Phys, 72 (1), 186-92
DOI 10.1016/j.ijrobp.2008.05.029, PubMed 18722269

Erikson A, Tufto I, Bjønnum AB, Bruland ØS, Davies Cde L (2008)
The impact of enzymatic degradation on the uptake of differently sized therapeutic molecules
Anticancer Res, 28 (6A), 3557-66
PubMed 19189635

Jebsen NL, Trovik CS, Bauer HC, Rydholm A, Monge OR, Hall KS, Alvegård T, Bruland OS (2008)
Radiotherapy to improve local control regardless of surgical margin and malignancy grade in extremity and trunk wall soft tissue sarcoma: a Scandinavian sarcoma group study
Int J Radiat Oncol Biol Phys, 71 (4), 1196-203
DOI 10.1016/j.ijrobp.2007.11.023, PubMed 18207661

Porojnicu AC, Bruland OS, Aksnes L, Grant WB, Moan J (2008)
Sun beds and cod liver oil as vitamin D sources
J Photochem Photobiol B, 91 (2-3), 125-31
DOI 10.1016/j.jphotobiol.2008.02.007, PubMed 18417354

Søvik A, Kippenes Skogmo H, Bruland ØS, Rune Olsen D, Malinen E (2008)
DCEMRI monitoring of canine tumors during fractionated radiotherapy
Acta Oncol, 47 (7), 1249-56
DOI 10.1080/02841860802244166, PubMed 18618342

Vågane R, Bruland ØS, Fosså SD, Olsen DR (2008)
Radiological and functional assessment of radiation-induced pulmonary damage following breast irradiation
Acta Oncol, 47 (2), 248-54
DOI 10.1080/02841860701630267, PubMed 18210300

Åmås KO, Bruland ØS, Brun M, Sivesind L (2008)
Life with cancer
Aschehoug, Oslo, 279 s.
BIBSYS 080460046, ISBN 978-82-0323584-9

Publications 2007

Aksnes LH, Bruland ØS (2007)
Some musculo-skeletal sequelae in cancer survivors
Acta Oncol, 46 (4), 490-6
DOI 10.1080/02841860701218642, PubMed 17497316

Berg A, Berner A, Lilleby W, Bruland ØS, Fosså SD, Nesland JM, Kvalheim G (2007)
Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy
Int J Cancer, 120 (8), 1603-9
DOI 10.1002/ijc.22488, PubMed 17230512

Berg A, Lilleby W, Bruland OS, Fosså SD (2007)
10-year survival and quality of life in patients with high-risk pN0 prostate cancer following definitive radiotherapy
Int J Radiat Oncol Biol Phys, 69 (4), 1074-83
DOI 10.1016/j.ijrobp.2007.04.031, PubMed 17703896

Dahle J, Borrebaek J, Jonasdottir TJ, Hjelmerud AK, Melhus KB, Bruland ØS, Press OW, Larsen RH (2007)
Targeted cancer therapy with a novel low-dose rate alpha-emitting radioimmunoconjugate
Blood, 110 (6), 2049-56
DOI 10.1182/blood-2007-01-066803, PubMed 17536011

Fauske L, Bruland ØS (2007)
Førstehjelp på tur: fjell-, høyde- og reisemedisin
Fri flyt, Oslo, 191 s.
BIBSYS 071693130, ISBN 978-82-996432-5-2

Larsen RH, Borrebaek J, Dahle J, Melhus KB, Krogh C, Valan MH, Bruland OS (2007)
Preparation of TH227-labeled radioimmunoconjugates, assessment of serum stability and antigen binding ability
Cancer Biother Radiopharm, 22 (3), 431-7
DOI 10.1089/cbr.2006.321, PubMed 17651051

Nilsson S, Franzén L, Parker C, Tyrrell C, Blom R, Tennvall J, Lennernäs B, Petersson U, Johannessen DC, Sokal M, Pigott K, Yachnin J, Garkavij M, Strang P, Harmenberg J, Bolstad B, Bruland OS (2007)
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study
Lancet Oncol, 8 (7), 587-94
DOI 10.1016/S1470-2045(07)70147-X, PubMed 17544845

Olsen DR, Bruland OS, Frykholm G, Norderhaug IN (2007)
Proton therapy - a systematic review of clinical effectiveness
Radiother Oncol, 83 (2), 123-32
DOI 10.1016/j.radonc.2007.03.001, PubMed 17499374

Porojnicu AC, Robsahm TE, Dahlback A, Berg JP, Christiani D, Bruland OS, Moan J (2007)
Seasonal and geographical variations in lung cancer prognosis in Norway. Does Vitamin D from the sun play a role?
Lung Cancer, 55 (3), 263-70
DOI 10.1016/j.lungcan.2006.11.013, PubMed 17207891

Søvik A, Malinen E, Skogmo HK, Bentzen SM, Bruland OS, Olsen DR (2007)
Radiotherapy adapted to spatial and temporal variability in tumor hypoxia
Int J Radiat Oncol Biol Phys, 68 (5), 1496-504
DOI 10.1016/j.ijrobp.2007.04.027, PubMed 17674980

Publications 2006

Aksnes LH, Hall KS, Folleraas G, Stenwig AE, Bjerkehagen B, Taksdal I, Winderen M, Bruland OS, Saeter G (2006)
Management of high-grade bone sarcomas over two decades: the Norwegian Radium Hospital experience
Acta Oncol, 45 (1), 38-46
DOI 10.1080/02841860500466624, PubMed 16464794

Bruland ØS (2006)
[Jumping after the Swedes]
Tidsskr Nor Laegeforen, 126 (5), 637
PubMed 16505887

Bruland ØS, Nilsson S, Fisher DR, Larsen RH (2006)
High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?
Clin Cancer Res, 12 (20 Pt 2), 6250s-6257s
DOI 10.1158/1078-0432.CCR-06-0841, PubMed 17062709

Dahle J, Borrebaek J, Melhus KB, Bruland OS, Salberg G, Olsen DR, Larsen RH (2006)
Initial evaluation of (227)Th-p-benzyl-DOTA-rituximab for low-dose rate alpha-particle radioimmunotherapy
Nucl Med Biol, 33 (2), 271-9
DOI 10.1016/j.nucmedbio.2005.12.004, PubMed 16546683

Jonasdottir TJ, Fisher DR, Borrebaek J, Bruland OS, Larsen RH (2006)
First in vivo evaluation of liposome-encapsulated 223Ra as a potential alpha-particle-emitting cancer therapeutic agent
Anticancer Res, 26 (4B), 2841-8
PubMed 16886603

Kaasa S, Brenne E, Lund JA, Fayers P, Falkmer U, Holmberg M, Lagerlund M, Bruland O (2006)
Prospective randomised multicenter trial on single fraction radiotherapy (8 Gy x 1) versus multiple fractions (3 Gy x 10) in the treatment of painful bone metastases
Radiother Oncol, 79 (3), 278-84
DOI 10.1016/j.radonc.2006.05.006, PubMed 16793154

Larsen RH, Saxtorph H, Skydsgaard M, Borrebaek J, Jonasdottir TJ, Bruland OS, Klastrup S, Harling R, Ramdahl T (2006)
Radiotoxicity of the alpha-emitting bone-seeker 223Ra injected intravenously into mice: histology, clinical chemistry and hematology
In Vivo, 20 (3), 325-31
PubMed 16724665

Lipton A, Berenson JR, Body JJ, Boyce BF, Bruland OS, Carducci MA, Cleeland CS, Clohisy DR, Coleman RE, Cook RJ, Guise TA, Pearse RN, Powles TJ, Rogers MJ, Roodman GD, Smith MR, Suva LJ, Vessella RL, Weilbaecher KN, King L (2006)
Advances in treating metastatic bone cancer: summary statement for the First Cambridge Conference
Clin Cancer Res, 12 (20 Pt 2), 6209s-6212s
DOI 10.1158/1078-0432.CCR-06-1213, PubMed 17062702

Malinen E, Søvik A, Hristov D, Bruland ØS, Olsen DR (2006)
Adapting radiotherapy to hypoxic tumours
Phys Med Biol, 51 (19), 4903-21
DOI 10.1088/0031-9155/51/19/012, PubMed 16985278

Søvik A, Malinen E, Bruland ØS, Bentzen SM, Olsen DR (2006)
Optimization of tumour control probability in hypoxic tumours by radiation dose redistribution: a modelling study
Phys Med Biol, 52 (2), 499-513
DOI 10.1088/0031-9155/52/2/013, PubMed 17202629

Publications 2005

Bruland OS, Høifødt H, Saeter G, Smeland S, Fodstad O (2005)
Hematogenous micrometastases in osteosarcoma patients
Clin Cancer Res, 11 (13), 4666-73
DOI 10.1158/1078-0432.CCR-05-0165, PubMed 16000559

Brustugun OT, Reed W, Poulsen JP, Bruland OS (2005)
Primary osteosarcoma of the breast
Acta Oncol, 44 (7), 767-70
DOI 10.1080/02841860500254897, PubMed 16227171

Dale E, Hellebust TP, Bruland ØS, Olsen DR (2005)
Comparative analyses of the dynamic properties of the bladder wall studied by repetitive pelvic CT scans of patients and cryo-sections of cadavers
Br J Radiol, 78 (930), 528-32
DOI 10.1259/bjr/82990907, PubMed 15900058

Eikenes L, Tari M, Tufto I, Bruland OS, de Lange Davies C (2005)
Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx) in human osteosarcoma xenografts
Br J Cancer, 93 (1), 81-8
DOI 10.1038/sj.bjc.6602626, PubMed 15942637

Henriksen G, Bruland OS, Larsen RH (2005)
Preparation and preclinical assessment of folate-conjugated, radiolabelled antibodies
Anticancer Res, 25 (1A), 9-15
PubMed 15816513

Nilsson S, Larsen RH, Fosså SD, Balteskard L, Borch KW, Westlin JE, Salberg G, Bruland OS (2005)
First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases
Clin Cancer Res, 11 (12), 4451-9
DOI 10.1158/1078-0432.CCR-04-2244, PubMed 15958630

Norum J, Bruland ØS, Spanne O, Bergmo T, Green T, Olsen DR, Olsen JH, Sjåeng EE, Burkow T (2005)
Telemedicine in radiotherapy: a study exploring remote treatment planning, supervision and economics
J Telemed Telecare, 11 (5), 245-50
DOI 10.1258/1357633054471858, PubMed 16035967

Onda M, Bruland ØS, Pastan I (2005)
TP-3 immunotoxins improve antitumor activity in mice with osteosarcoma
Clin Orthop Relat Res (430), 142-8
DOI 10.1097/01.blo.0000137544.30200.b6, PubMed 15662316

Publications 2004

Bruheim S, Bruland OS, Breistol K, Maelandsmo GM, Fodstad O (2004)
Human osteosarcoma xenografts and their sensitivity to chemotherapy
Pathol Oncol Res, 10 (3), 133-41
DOI 10.1007/BF03033741, PubMed 15448748

Eikenes L, Bruland ØS, Brekken C, Davies Cde L (2004)
Collagenase increases the transcapillary pressure gradient and improves the uptake and distribution of monoclonal antibodies in human osteosarcoma xenografts
Cancer Res, 64 (14), 4768-73
DOI 10.1158/0008-5472.CAN-03-1472, PubMed 15256445

Henriksen G, Bruland OS, Larsen RH (2004)
Thorium and actinium polyphosphonate compounds as bone-seeking alpha particle-emitting agents
Anticancer Res, 24 (1), 101-5
PubMed 15015582

Henriksen G, Schoultz BW, Michaelsen TE, Bruland ØS, Larsen RH (2004)
Sterically stabilized liposomes as a carrier for alpha-emitting radium and actinium radionuclides
Nucl Med Biol, 31 (4), 441-9
DOI 10.1016/j.nucmedbio.2003.11.004, PubMed 15093814

Mikkelsen IM, Løkke C, Flagstad T, Bruland ØS (2004)
Interferon-γ Sensitises Human Osteosarcoma Cells to Trail-mediated Apoptosis
Cancer Genomics Proteomics, 1 (2), 95-104
PubMed 31394674

Publications 2003

Dale E, Hellebust TP, Bruland ØS, Olsen DR (2003)
Comparative analyses of the dynamic properties of the rectum studied by cryo-sections of human cadavers and pelvic CT scans of patients
Br J Radiol, 76 (902), 104-8
DOI 10.1259/bjr/75640835, PubMed 12642278

Henriksen G, Fisher DR, Roeske JC, Bruland ØS, Larsen RH (2003)
Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice
J Nucl Med, 44 (2), 252-9
PubMed 12571218

Olstad OK, Gautvik VT, Reppe S, Rian E, Jemtland R, Ohlsson C, Bruland OS, Gautvik KM (2003)
Molecular heterogeneity in human osteosarcoma demonstrated by enriched mRNAs isolated by directional tag PCR subtraction cloning
Anticancer Res, 23 (3B), 2201-16
PubMed 12894494

Weinholdt T, Bruland ØS, Hornburg M, Bruland Ø (2003)
Hei, jeg er vennen din!
Dinamo effekt, Healthcare, [Lysaker], 35 s.
BIBSYS 031722334, ISBN 82-8111-000-7

Publications 2002

Anderson PM, Wiseman GA, Dispenzieri A, Arndt CA, Hartmann LC, Smithson WA, Mullan BP, Bruland OS (2002)
High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases
J Clin Oncol, 20 (1), 189-96
DOI 10.1200/JCO.2002.20.1.189, PubMed 11773169

Aurlien E, Kvinnsland Y, Larsen RH, Bruland ØS (2002)
Radiation doses to non-Hodgkin's lymphoma cells and normal bone marrow exposed in vitro. Comparison of an alpha-emitting radioimmunoconjugate and external gamma-irradiation
Int J Radiat Biol, 78 (2), 133-42
DOI 10.1080/09553000110094788, PubMed 11779363

Henriksen G, Breistøl K, Bruland ØS, Fodstad Ø, Larsen RH (2002)
Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model
Cancer Res, 62 (11), 3120-5
PubMed 12036923

Kvinnsland Y, Bruland O, Moe L, Skretting A (2002)
A method for measurement of the uptake patterns of two beta-emitting radionuclides in the same tissue section with a digital silicon detector: application to a study of 89SrCl2 and 153Sm-EDTMP in a dog with spontaneous osteosarcoma
Eur J Nucl Med Mol Imaging, 29 (2), 191-7
DOI 10.1007/s00259-001-0693-1, PubMed 11926381

Ree AH, Bratland A, Kroes RA, Aasheim HC, Flørenes VA, Moskal JR, Fodstad O, Bruland OS, Maelandsmo GM (2002)
Clinical and cell line specific expression profiles of a human gene identified in experimental central nervous system metastases
Anticancer Res, 22 (4), 1949-57
PubMed 12174869

Saeter G, Hall KS, Bruland ØS, Solheim ØP, Høie J, Follerås G, Helgerud P, Stenwig AE, Bjerkehagen B, Talle K, Taksdal I, Winderen M (2002)
[Bone and soft tissue sarcomas treated at the Norwegian Radium Hospital 1980-99]
Tidsskr Nor Laegeforen, 122 (21), 2089-94
PubMed 12555642

Publications 2001

Hassfjell S, Ingebrigtsen K, Bruland ØS (2001)
Synthesis, purification and biodistribution of (205)Bi-DOTMP, visualizing bone deposition patterns with autoradiography
Nucl Med Biol, 28 (4), 425-33
DOI 10.1016/s0969-8051(01)00202-5, PubMed 11395316

Kvinnsland Y, Skretting A, Bruland OS (2001)
Radionuclide therapy with bone-seeking compounds: Monte Carlo calculations of dose-volume histograms for bone marrow in trabecular bone
Phys Med Biol, 46 (4), 1149-61
DOI 10.1088/0031-9155/46/4/317, PubMed 11324957

Onda M, Olafsen T, Tsutsumi Y, Bruland OS, Pastan I (2001)
Cytotoxicity of antiosteosarcoma recombinant immunotoxins composed of TP-3 Fv fragments and a truncated Pseudomonas exotoxin A
J Immunother, 24 (2), 144-50
DOI 10.1097/00002371-200103000-00009, PubMed 11265772

Publications 2000

Aurlien E, Larsen RH, Akabani G, Olsen DR, Zalutsky MR, Bruland OS (2000)
Exposure of human osteosarcoma and bone marrow cells to tumour-targeted alpha-particles and gamma-irradiation: analysis of cell survival and microdosimetry
Int J Radiat Biol, 76 (8), 1129-41
DOI 10.1080/09553000050111604, PubMed 10947126

Aurlien E, Larsen RH, Kvalheim G, Bruland OS (2000)
Demonstration of highly specific toxicity of the alpha-emitting radioimmunoconjugate(211)At-rituximab against non-Hodgkin's lymphoma cells
Br J Cancer, 83 (10), 1375-9
DOI 10.1054/bjoc.2000.1453, PubMed 11044364

Braendengen M, Bruland OS, Olsen DR (2000)
[Radiotherapy of skeletal metastases]
Tidsskr Nor Laegeforen, 120 (16), 1870-4
PubMed 10925615

Brekken C, Bruland ØS, de Lange Davies C (2000)
Interstitial fluid pressure in human osteosarcoma xenografts: significance of implantation site and the response to intratumoral injection of hyaluronidase
Anticancer Res, 20 (5B), 3503-12
PubMed 11131654

Brekken C, Hjelstuen MH, Bruland ØS, de Lange Davies C (2000)
Hyaluronidase-induced periodic modulation of the interstitial fluid pressure increases selective antibody uptake in human osteosarcoma xenografts
Anticancer Res, 20 (5B), 3513-9
PubMed 11131655

Pihl A, Bruland OS (2000)
Oral presentations in science and medicine. An art in decline?
Anticancer Res, 20 (5A), 2795-9
PubMed 11062686

Publications 1999

Jemtland R, Rian E, Olstad OK, Haug E, Bruland OS, Bucht E, Gautvik KM (1999)
Two human osteoblast-like osteosarcoma cell lines show distinct expression and differential regulation of parathyroid hormone-related protein
J Bone Miner Res, 14 (6), 904-14
DOI 10.1359/jbmr.1999.14.6.904, PubMed 10352098

Larsen RH, Murud KM, Akabani G, Hoff P, Bruland OS, Zalutsky MR (1999)
211At- and 131I-labeled bisphosphonates with high in vivo stability and bone accumulation
J Nucl Med, 40 (7), 1197-203
PubMed 10405142

Murud KM, Larsen RH, Bruland OS, Hoff P (1999)
Influence of pretreatment with 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APB) on organ uptake of 211At and 125I-labeled amidobisphosphonates in mice
Nucl Med Biol, 26 (7), 791-4
DOI 10.1016/s0969-8051(99)00047-5, PubMed 10628558

Olafsen T, Munthe Lund CK, Bruland OS, Sandlie I, Michaelsen TE (1999)
Complement-mediated lysis of cultured osteosarcoma cell lines using chimeric mouse/human TP-1 IgG1 and IgG3 antibodies
Cancer Immunol Immunother, 48 (7), 411-8
DOI 10.1007/s002620050594, PubMed 10501855

Ree AH, Tvermyr M, Engebraaten O, Rooman M, Røsok O, Hovig E, Meza-Zepeda LA, Bruland OS, Fodstad O (1999)
Expression of a novel factor in human breast cancer cells with metastatic potential
Cancer Res, 59 (18), 4675-80
PubMed 10493524

Tanum G, Bruland OS, Hjelle D, Reitan JB (1999)
[Patient treatment in radiation accidents]
Tidsskr Nor Laegeforen, 119 (10), 1446-50
PubMed 10354753

Aas M, Moe L, Gamlem H, Skretting A, Ottesen N, Bruland OS (1999)
Internal radionuclide therapy of primary osteosarcoma in dogs, using 153Sm-ethylene-diamino-tetramethylene-phosphonate (EDTMP)
Clin Cancer Res, 5 (10 Suppl), 3148s-3152s
PubMed 10541356

Publications 1998

Bruland ØS (1998)
Towards the eradication of osteosarcoma metastases 30.8. - 1.9. 1998 an odyssey: the evolution of osteosarcoma therapy the coastal express"Richard With", sailing from Trondheim to Tromsø
Wyeth Lederle, [s.l.], 136 s.
BIBSYS 031294499, ISBN 82-91929-02-5

Hassfjell SP, Skretting A, Bruland OS, Hoff P (1998)
Predicting detectability in radioguided surgery: a study based on physical characterization of the probe and on tissue uptake ratios of 125I-, 153Sm- and 165Er-labelled radiopharmaceuticals
Nucl Med Commun, 19 (3), 207-17
DOI 10.1097/00006231-199803000-00004, PubMed 9625495

Larsen RH, Bruland OS (1998)
Intratumour injection of immunoglobulins labelled with the alpha-particle emitter 211At: analyses of tumour retention, microdistribution and growth delay
Br J Cancer, 77 (7), 1115-22
DOI 10.1038/bjc.1998.185, PubMed 9569048

Lopes JM, Hannisdal E, Bjerkehagen B, Bruland OS, Danielsen HE, Pettersen EO, Sobrinho-Simões M, Nesland JM (1998)
Synovial sarcoma. Evaluation of prognosis with emphasis on the study of DNA ploidy and proliferation (PCNA and Ki-67) markers
Anal Cell Pathol, 16 (1), 45-62
DOI 10.1155/1998/545906, PubMed 9584899

Olafsen T, Rasmussen IB, Norderhaug L, Bruland OS, Sandlie I (1998)
IgM secretory tailpiece drives multimerisation of bivalent scFv fragments in eukaryotic cells
Immunotechnology, 4 (2), 141-53
DOI 10.1016/s1380-2933(98)00014-1, PubMed 9853955

Olsen DR, Bruland OS (1998)
Radiotherapy in Scandinavia
Acta Oncol, 37 (6), 553-60
DOI 10.1080/028418698430250, PubMed 9860313

Publications 1997

Bruland OS, Pihl A (1997)
On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy
Eur J Cancer, 33 (11), 1725-31
DOI 10.1016/s0959-8049(97)00252-9, PubMed 9470825

Ekstrøm PO, Giercksky KE, Andersen A, Bruland OS, Slørdal L (1997)
Intratumoral differences in methotrexate levels within human osteosarcoma xenografts studied by microdialysis
Life Sci, 61 (19), PL275-80
DOI 10.1016/s0024-3205(97)00839-4, PubMed 9364204

Hassfjell SP, Bruland OS, Hoff P (1997)
212Bi-DOTMP: an alpha particle emitting bone-seeking agent for targeted radiotherapy
Nucl Med Biol, 24 (3), 231-7
DOI 10.1016/s0969-8051(97)00059-0, PubMed 9228657

Lopes JM, Bruland OS, Bjerkehagen B, Silva MC, Holm R, Pettersen EO, Solheim OP, Sobrinho-Simões M, Nesland JM (1997)
Synovial sarcoma: immunohistochemical expression of P-glycoprotein and glutathione S transferase-pi and clinical drug resistance
Pathol Res Pract, 193 (1), 21-36
DOI 10.1016/s0344-0338(97)80090-8, PubMed 9112270

Publications 1996

Bruland OS, Skretting A, Solheim OP, Aas M (1996)
Targeted radiotherapy of osteosarcoma using 153 Sm-EDTMP. A new promising approach
Acta Oncol, 35 (3), 381-4
DOI 10.3109/02841869609101655, PubMed 8679270

Gordeladze JO, Lund HW, Jablonski G, Bruland OS (1996)
Diverse expression of G-proteins in human sarcoma cell lines with different osteogenic potential: evidence for the involvement of Gi2 in cell proliferation
J Cell Biochem, 60 (1), 95-106
DOI 10.1002/(SICI)1097-4644(19960101)60:1%3C95::AID-JCB12%3E3.0.CO;2-J, PubMed 8825419

Moe L, Boysen M, Aas M, Lønaas L, Gamlem H, Bruland OS (1996)
Maxillectomy and targeted radionuclide therapy with 153Sm-EDTMP in a recurrent canine osteosarcoma
J Small Anim Pract, 37 (5), 241-6
DOI 10.1111/j.1748-5827.1996.tb01782.x, PubMed 8736231

Olafsen T, Bruland OS, Zalutsky MR, Sandlie I (1996)
Abundant tyrosine residues in the antigen binding site in anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: Application to radiolabeling
Acta Oncol, 35 (3), 297-301
DOI 10.3109/02841869609101644, PubMed 8679259

Saeter G, Bruland OS, Follerås G, Boysen M, Høie J (1996)
Extremity and non-extremity high-grade osteosarcoma -- the Norwegian Radium Hospital experience during the modern chemotherapy era
Acta Oncol, 35 Suppl 8, 129-34
DOI 10.3109/02841869609098531, PubMed 9073059

Publications 1995

Bruland OS (1995)
Cancer therapy with radiolabeled antibodies. An overview
Acta Oncol, 34 (8), 1085-94
DOI 10.3109/02841869509127235, PubMed 8608033

Larsen RH, Hoff P, Vergote IB, Bruland OS, Aas M, De Vos L, Nustad K (1995)
Alpha-particle radiotherapy with 211At-labeled monodisperse polymer particles, 211At-labeled IgG proteins, and free 211At in a murine intraperitoneal tumor model
Gynecol Oncol, 57 (1), 9-15
DOI 10.1006/gyno.1995.1093, PubMed 7705707

Olafsen T, Bruland OS, Zalutsky MR, Sandlie I (1995)
Cloning and sequencing of V genes from anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: location of lysine residues and implications for radiolabeling
Nucl Med Biol, 22 (6), 765-71
DOI 10.1016/0969-8051(95)00014-o, PubMed 8535337

Publications 1994

Bruland OS, Fodstad O, Aas M, Solheim OP, Høie J, Skretting A, Winderen M, Michaelsen T, Pihl A (1994)
Immunoscintigraphy of bone sarcomas--results in 5 patients
Eur J Cancer, 30A (10), 1484-9
DOI 10.1016/0959-8049(94)00304-n, PubMed 7833107

Larsen RH, Bruland OS, Hoff P, Alstad J, Lindmo T, Rofstad EK (1994)
Inactivation of human osteosarcoma cells in vitro by 211At-TP-3 monoclonal antibody: comparison with astatine-211-labeled bovine serum albumin, free astatine-211 and external-beam X rays
Radiat Res, 139 (2), 178-84
DOI 10.2307/3578662, PubMed 8052693

Larsen RH, Bruland OS, Hoff P, Alstad J, Rofstad EK (1994)
Analysis of the therapeutic gain in the treatment of human osteosarcoma microcolonies in vitro with 211At-labelled monoclonal antibody
Br J Cancer, 69 (6), 1000-5
DOI 10.1038/bjc.1994.196, PubMed 8198960

Page RL, Garg PK, Garg S, Archer GE, Bruland OS, Zalutsky MR (1994)
PET imaging of osteosarcoma in dogs using a fluorine-18-labeled monoclonal antibody Fab fragment
J Nucl Med, 35 (9), 1506-13
PubMed 8071702

Publications 1993

Andreassen A, Oyjord T, Hovig E, Holm R, Flørenes VA, Nesland JM, Myklebost O, Høie J, Bruland OS, Børresen AL (1993)
p53 abnormalities in different subtypes of human sarcomas
Cancer Res, 53 (3), 468-71
PubMed 8425179

Publications 1992

Flørenes VA, Aamdal S, Myklebost O, Maelandsmo GM, Bruland OS, Fodstad O (1992)
Levels of nm23 messenger RNA in metastatic malignant melanomas: inverse correlation to disease progression
Cancer Res, 52 (21), 6088-91
PubMed 1356624

Haines DM, Bruland OS, Matte G, Wilkinson AA, Meric SM, Fowler JD (1992)
Immunoscintigraphic detection of primary and metastatic spontaneous canine osteosarcoma with F(ab')2 fragments of osteosarcoma-associated monoclonal antibody TP-1
Anticancer Res, 12 (6B), 2151-7
PubMed 1295462

Publications 1990

Fjeld JG, Bruland OS, Benestad HB, Schjerven L, Stigbrand T, Nustad K (1990)
Radioimmunotargeting of human tumour cells in immunocompetent animals
Br J Cancer, 62 (4), 573-8
DOI 10.1038/bjc.1990.332, PubMed 2223574

Publications 1989

Haines DM, Bruland OS (1989)
Immunohistochemical detection of osteosarcoma-associated antigen in canine osteosarcoma
Anticancer Res, 9 (4), 903-7
PubMed 2684000

Publications 1988

Bruland OS, Fodstad O, Stenwig AE, Pihl A (1988)
Expression and characteristics of a novel human osteosarcoma-associated cell surface antigen
Cancer Res, 48 (18), 5302-9
PubMed 2457439

Bruland ØS (1988)
Preparation and properties of two novel highly specific antisarcoma monoclonal antibodies and their application in thecharacterization and diagnoses of human sarcomas
The Norwegian cancer society, <Oslo>, 1 b. (flere pag.)
BIBSYS 894061631, ISBN 82-90187-45-9